Related Experiment Video
Updated: Feb 1, 2026
06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
10.2K
JAK Inhibitors for Atopic Dermatitis: An Update
Helen He1, Emma Guttman-Yassky2,3
1Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, 5 E. 98th Street, New York, NY, 10029, USA.
American Journal of Clinical Dermatology
|December 12, 2018
Summary
Atopic dermatitis treatments are advancing with Janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitors. These therapies target key inflammatory pathways, offering new hope for managing this common skin condition.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a prevalent inflammatory skin condition characterized by skin barrier dysfunction and immune dysregulation.
- Key immune pathways involved include T helper (Th) 2, Th22, Th1, and Th17 cells, driven by various cytokines.
- Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and spleen tyrosine kinase (SYK) pathways mediate crucial signaling in AD pathogenesis.
Purpose of the Study:
- To review the efficacy and safety of JAK and SYK inhibitors in treating atopic dermatitis.
- To elucidate the complex molecular interactions driving AD.
- To highlight the unmet need for targeted and safe long-term therapeutic options for AD.
Main Methods:
- Review of current literature on JAK and SYK inhibitors for AD treatment.
- Analysis of data on the efficacy and safety profiles of these inhibitors.
- Exploration of the molecular mechanisms underlying AD and targeted therapies.
Main Results:
- JAK inhibitors demonstrate efficacy in reducing AD severity and symptoms.
- Topical and oral JAK inhibitors are emerging as promising therapeutic options.
- Understanding of JAK and SYK pathway involvement in AD is expanding.
Conclusions:
- JAK and SYK inhibitors represent a promising therapeutic avenue for atopic dermatitis.
- Targeting multiple immune axes is crucial due to AD's heterogeneity.
- Further research is needed to optimize the use and safety of these inhibitors for long-term AD management.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
12.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.5K
01:52Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
01:23Dipeptidyl Peptidase 4 Inhibitors
669
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
669
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
601
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
601